An observational study in Heart Failure With Reduced Ejection Fraction and HFrEF - Heart Failure With Reduced Ejection Fraction, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Assiut University · Observational
This prospective observational study aims to evaluate intermediate clinical, renal, and functional outcomes in patients with heart failure with reduced ejection fraction treated with contemporary guideline-directed medical therapy over a 6 to 12 month follow-up period.
Guideline-directed medical therapy (GDMT) is the cornerstone of treatment for heart failure with reduced ejection fraction. This observational study will enroll adult patients with chronic HFrEF (LVEF ≤ 40%) who are stable on or planned to initiate GDMT.
Patients will be followed for 6 to 12 months to assess changes in renal function, functional status, quality of life, left ventricular ejection fraction, hospitalization rates, and medication adherence.
Adult patients with chronic heart failure with reduced ejection fraction attending the Cardiovascular Department at Assiut University.
Exclusion Criteria:
Adult patients with heart failure with reduced ejection fraction who are receiving or planned to receive contemporary guideline-directed medical therapy and will be followed for intermediate outcomes.
Change in NYHA functional class
Change in New York Heart Association (NYHA) functional class from baseline to follow-up.
Time frame: Baseline and at 6 to 12 months
Change in KCCQ-12 score
Change in Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) total score from baseline to follow-up (range 0-100, higher scores indicate better health status).
Time frame: From baseline to 6 to 12 months
Change in left ventricular ejection fraction
Change in left ventricular ejection fraction (LVEF) measured by echocardiography from baseline to follow-up.
Time frame: From baseline to 6 to 12 months
Change in estimated glomerular filtration rate
Change in estimated glomerular filtration rate (eGFR) calculated by CKD-EPI equation from baseline to follow-up.
Time frame: From baseline to 6 to 12 months
Rate of heart failure hospitalization
Number of heart failure-related hospital admissions during the follow-up period.
Time frame: From baseline to 6 to 12 months
Proportion of patients on each GDMT component
Proportion of patients prescribed each of the four foundational GDMT drug classes at follow-up.
Time frame: At 6 to 12 months
Medication adherence score
Mean Morisky Medication Adherence Scale-8 (MMAS-8) score (range 0-8, higher scores indicate better adherence).
Time frame: At 6 to 12 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University